C. Meier et al., TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinicalsymptoms in subclinical hypothyroidism: A double blind, placebo-controlledtrial (basel thyroid study), J CLIN END, 86(10), 2001, pp. 4860-4866
This study evaluated the effect of physiological, TSH-guided, L-thyroxine t
reatment on serum lipids and clinical symptoms in patients with subclinical
hypothyroidism. Sixty-six women with proven subclinical hypothyroidism (TS
H, 11.7 +/- 0.8 mIU/ liter) were randomly assigned to receive L-thyroxine o
r placebo for 48 wk. Individual L-thyroxine replacement (mean dose, 85.5 +/
- 4.3 mug/d) was performed based on blinded TSH monitoring, resulting in eu
thyroid TSH levels (3.1 +/- 0.3 mIU/ liter). Lipid concentrations and clini
cal scores were measured before and after treatment. Sixty-three of 66 pati
ents completed the study. In the L-thyroxine group (n = 31) total cholester
ol and low density lipoprotein cholesterol were significantly reduced [-0.2
4 mmol/liter, 3.8% (P = 0.015) and -0.33 mmol/liter, 8.2% (P = 0.004), resp
ectively]. Low density lipoprotein cholesterol decrease was more pronounced
in patients with TSH levels greater than 12 mIU/liter or elevated low dens
ity lipoprotein cholesterol levels at baseline. A significant decrease in a
polipoprotein B-100 concentrations was observed (P = 0.037), whereas high d
ensity lipoprotein cholesterol, triglycerides, apolipoprotein Al, and lipop
rotein(a) levels remained unchanged. Two clinical scores assessing symptoms
and signs of hypothyroidism (Billewicz and Zulewski scores) improved signi
ficantly (P = 0.02).
This is the first double blind study to show that physiological L-thyroxine
replacement in patients with subclinical hypothyroidism has a beneficial e
ffect on low density lipo. protein cholesterol levels and clinical symptoms
of hypothyroidism. An important risk reduction of cardiovascular mortality
of 9-31% can be estimated from the observed improvement in low density lip
oprotein cholesterol.